Properties of Factorial Cumulant to Factorial Moment Ratio

It is shown that the ratio of factorial cumulant moments to factorial moments for a multiplicity distribution truncated in the tail reveals oscillations in sign similar to those observed in experimental data. It is suggested that this effect be taken into account in the analysis of data in order to obtain correct physical information on the multiplicity distributions.Comment: (LaTeX + epsfig, 8 pages including 3 PostScript figures, all encoded via uufiles), DFTT 46/9

Clan Properties in Parton Showers

By considering clans as genuine elementary subprocesses, i.e., intermediate parton sources in the Simplified Parton Shower model, a generalized version of this model is defined. It predicts analytically clan properties at parton level in agreement with the general trends observed experimentally at hadronic level and in Monte Carlo simulations both at partonic and hadronic level. In particular the model shows a linear rising in rapidity of the average number of clans at fixed energy of the initial parton and its subsequent bending for rapidity intervals at the border of phase space, and approximate energy independence of the average number of clans in fixed rapidity intervals. The energy independence becomes stricter by properly normalizing the average number of clans.Comment: (27 pages in Plain TeX plus 10 Postscript Figures, all compressed via uufiles) DFTT 7/9

Clan Structure in Rapidity Intervals

We present a cascading model for a single jet, inspired to QCD and to the phenomenological analysis of multiplicity distributions. The model, describing as it does a two dimensional evolution in virtuality and rapidity, allows analytical predictions for clan analysis parameters to be made.Comment: Talk presented by R. Ugoccioni at XXV Multiparticle Dynamics, Stara Lesna, Slovakia, Sept. 1995. LaTeX with epsfig, 11 pages, 3 figures. Postscript file available through http://www.thep.lu.se/tf2/hep/article.hep.htm

Maps of zeroes of the grand canonical partition function in a statistical model of high energy collisions

Theorems on zeroes of the truncated generating function in the complex plane are reviewed. When examined in the framework of a statistical model of high energy collisions based on the negative binomial (Pascal) multiplicity distribution, these results lead to maps of zeroes of the grand canonical partition function which allow to interpret in a novel way different classes of events in pp collisions at LHC c.m. energies.Comment: 17 pages, figures (ps included); added references, some figures enlarged. To appear in J. Phys.

Is there a role for dual PI3K/mTOR inhibitors for patients affected with lymphoma?

The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti-cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical responses, including complete remissions (especially in follicular lymphoma patients), are also observed in the very few clinical studies performed in patients that are affected by relapsed/refractory lymphomas or chronic lymphocytic leukemia. In this review, we summarize the literature on dual PI3K/mTOR inhibitors focusing on the lymphoma setting, presenting both the three compounds still in clinical development and those with a clinical program stopped or put on hold

Inside perspective of the synthetic and computational toolbox of JAK inhibitors: Recent updates

The mechanisms of inflammation and cancer are intertwined by complex networks of signaling pathways. Dysregulations in the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway underlie several pathogenic conditions related to chronic inflammatory states, autoimmune diseases and cancer. Historically, the potential application of JAK inhibition has been thoroughly explored, thus triggering an escalation of favorable results in this field. So far, five JAK inhibitors have been approved by the Food and Drug Administration (FDA) for the treatment of different diseases. Considering the complexity of JAK-depending processes and their involvement in multiple disorders, JAK inhibitors are the perfect candidates for drug repurposing and for the assessment of multitarget strategies. Herein we reviewed the recent progress concerning JAK inhibition, including the innovations provided by the release of JAKs crystal structures and the improvement of synthetic strategies aimed to simplify of the industrial scale-up